Life sciences stories
Rising demand for faster AI-ready infrastructure is driving EfficiencyIT's expansion, as Giles Pattison joins to help scale its modular data centre business.
The rankings bolster Altimetrik's push to win larger contracts from drugmakers as life sciences firms seek AI that improves regulated operations.
Search now blends text, images and files as Google rolls out a single AI experience and background agents to over 1 billion users.
Researchers will gain tools to cut literature review and modelling time as Google opens access to experimental Gemini for Science features gradually.
The UK industrial AI company is stepping up its North American push as it seeks to turn existing US customers into broader revenue growth.
Search users will get background AI agents and custom layouts as Google broadens Gemini across its apps, YouTube and Workspace.
The move will put AVEVA's industrial data platform on AWS, giving customers more cloud choice and access to AI tools across operations.
Poor data quality has been slowing enterprise AI roll-outs, prompting Denodo to link live governed data to AWS agentic tools across multiple services.
The purchase will add more than 1,000 Azure engineers and AI specialists as NTT Data targets larger enterprise roll-outs on Microsoft cloud tools.
The cornerstone commitment should help Longwall Ventures reach a GBP £100 million close and back more UK deep tech start-ups.
The tech cluster supports more than 63,000 jobs and could help Canada strengthen domestic supply chains for semiconductors and photonics.
The move comes as AI demand drives Britain's data centre operators to expand faster, secure more power and plan larger sites.
Foreign backers now supply up to 90% of capital in Canada's biggest venture rounds, widening concerns over ownership and economic sovereignty.
The grants are set to speed the rollout of AI tools across healthcare, manufacturing and finance, helping GTA firms reach market sooner.
Ireland's investor appeal held up even as European foreign direct investment fell 7% to a decade low, EY found.
The platform is aimed at regulated industries and sensitive data users, with on-premise and air-gapped deployment to keep control in-house.
Drug makers face new filing deadlines in China, as eligible trial data can now be shielded for up to six years from copycat use.
The pact will widen use of AI in Singapore's public services, schools and labs, while adding new tests on safety, governance and inclusion.
EY-Parthenon says dealmaking is shifting towards AI and technology as 87% of UK chief executives expect their M&A appetite to rise.
The brownfield deal could ease capacity pressure in London, where cloud providers and AI users are competing for scarce land and power.
